Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

636 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Long GV, et al. Among authors: davies ma. Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8. Lancet Oncol. 2012. PMID: 23051966 Clinical Trial.
NRAS mutation status is an independent prognostic factor in metastatic melanoma.
Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. Jakob JA, et al. Among authors: davies ma. Cancer. 2012 Aug 15;118(16):4014-23. doi: 10.1002/cncr.26724. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180178 Free PMC article.
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Davies MA, et al. Clin Cancer Res. 2012 Feb 15;18(4):1120-8. doi: 10.1158/1078-0432.CCR-11-2436. Epub 2012 Jan 5. Clin Cancer Res. 2012. PMID: 22223528 Free PMC article. Clinical Trial.
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
Beasley GM, Coleman AP, Raymond A, Sanders G, Selim MA, Peterson BL, Brady MS, Davies MA, Augustine C, Tyler DS. Beasley GM, et al. Among authors: davies ma. Ann Surg Oncol. 2012 Nov;19(12):3896-3905. doi: 10.1245/s10434-012-2373-8. Epub 2012 May 2. Ann Surg Oncol. 2012. PMID: 22549288 Free PMC article. Clinical Trial.
BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. Kim J, et al. Among authors: davies ma. J Cutan Pathol. 2012 Sep;39(9):821-5. doi: 10.1111/j.1600-0560.2012.01950.x. Epub 2012 Jul 19. J Cutan Pathol. 2012. PMID: 22809251 Free PMC article. Clinical Trial.
Targeted therapy for brain metastases.
Davies MA. Davies MA. Adv Pharmacol. 2012;65:109-42. doi: 10.1016/B978-0-12-397927-8.00005-1. Adv Pharmacol. 2012. PMID: 22959025 Review.
636 results